Transition Therapeutics Company Profile (NASDAQ:TTHI)

About Transition Therapeutics

Transition Therapeutics Inc. is a product-focused biopharmaceutical company. The Company's principal business activity is the researching and developing of therapeutic agents. The Company is developing therapeutics for central nervous system (CNS) and metabolic disease indications. The Company's technologies are focused on the treatment of agitation and aggression in Alzheimer's disease and diabetes. The Company's subsidiary, Transition Therapeutics Ireland Limited (Transition Ireland), is developing two drug candidates: neuropsychiatric candidate ELND005 and androgen deficiency candidate TT701. The Company's subsidiary, Waratah Pharmaceuticals Inc. (Waratah), is developing diabetes drug candidate TT401. The Company's other two entities provide development services in support of the clinical and non-clinical activities of Transition Ireland and Waratah.

Industry, Sector and Symbol:

Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Exchange: NASDAQ
Symbol: TTHI
CUSIP:

Key Metrics:

Previous Close: $1.52
50 Day Moving Average: $1.5853
200 Day Moving Average: $1.1095
52-Week Range: $0.66 - $2.75
Trailing P/E Ratio: N/A
Foreward P/E Ratio: -2.58
P/E Growth: 0.0000
Market Cap: $N/A
Beta: 1.59

Additional Links:

Companies Related to Transition Therapeutics:

Consensus Ratings for Transition Therapeutics (NASDAQ:TTHI) (?)

Ratings Breakdown:	2 Hold Ratings
Consensus Rating:	Hold (Score: 2.00)
Consensus Price Target:	$1.50 (1.63% downside)

Analysts' Ratings History for Transition Therapeutics (NASDAQ:TTHI)

Show:

Date	Firm	Action	Rating	Price Target
5/14/2016	Cowen and Company	Reiterated Rating	Hold
4/19/2016	Canaccord Genuity	Reiterated Rating	Hold
2/11/2015	HC Wainwright	Reiterated Rating	Buy	$10.00

(Data available from 9/28/2014 forward)

Earnings History for Transition Therapeutics (NASDAQ:TTHI)

Date	Quarter	Consensus Estimate	Actual EPS	Release Link	Conference Call
9/15/2015	Q415	($0.39)	($0.31)	View	N/A
5/12/2015	Q315	($0.20)	($0.11)	View	N/A
2/10/2015		($0.24)	($0.38)	View	N/A
11/12/2014	Q312	($0.18)	($0.45)	View	N/A
9/26/2014		($0.28)	($0.39)	View	N/A
5/14/2014		($0.07)	($0.16)	View	N/A
11/12/2013		($0.11)	($0.08)	View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Transition Therapeutics (NASDAQ:TTHI)

Current Year EPS Consensus Estimate: $-0.3400 EPS
Next Year EPS Consensus Estimate: $-0.5900 EPS

Dividend History for Transition Therapeutics (NASDAQ:TTHI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Transition Therapeutics (NASDAQ:TTHI)
No insider trades for this company have been tracked by MarketBeat.com

Latest Headlines for Transition Therapeutics (NASDAQ:TTHI)

Date	Headline
	Transition Therapeutics Announces Special Shareholder Meeting Voting Results Including Shareholder Approval … (NASDAQ:TTHI) finance.yahoo.com - August 26 at 7:33 PM
	OPKO Health (OPK) Announces Transition Therapeutics (TTHI) Shareholder Approval of Proposed Acquisition (NASDAQ:TTHI) www.streetinsider.com - August 26 at 10:49 AM
	8:53 am Transition Therapeutics shareholders approve merger with OPKO health (OPK (NASDAQ:TTHI) finance.yahoo.com - August 26 at 10:49 AM
	Transition (TTHI) Stock Up on News of Acquisition by Opko (NASDAQ:TTHI) finance.yahoo.com - July 1 at 8:59 AM
	Here’s Why Traders Are Watching These Five Stocks Today (NASDAQ:TTHI) www.insidermonkey.com - June 30 at 10:40 AM
	Transition Therapeutics Ord (NASDAQ:TTHI) Short Interest Decreased By 12.21% - Wall Street Hints and News (NASDAQ:TTHI) hintsnewsnetwork.com - May 27 at 2:38 PM
	Transition Therapeutics, Inc. (TTHI) Broker Price Targets For The Coming Week - Share Trading News (NASDAQ:TTHI) www.sharetrading.news - May 24 at 3:03 PM
	Revenue Update on Transition Therapeutics Inc (USA)(NASDAQ:TTHI) - Trade Calls (NASDAQ:TTHI) www.tradecalls.org - May 20 at 2:47 PM
	Phil Kessel scores twice as Pittsburgh Penguins eliminate Washington Capitals with 4-3 victory in OT (NASDAQ:TTHI) www.theprovince.com - May 12 at 9:19 AM
	Transition Therapeutics posts 3Q loss (NASDAQ:TTHI) sg.finance.yahoo.com - May 11 at 4:23 PM
	Transition Therapeutics Announces Third Quarter Fiscal 2016 Financial Results (NASDAQ:TTHI) finance.yahoo.com - May 11 at 4:01 PM
	Transition Therapeutics to Hold Conference Call on Third Quarter Fiscal 2016 Financial Results on Wednesday, May 11th, at 4:30 P.M. EST (NASDAQ:TTHI) finance.yahoo.com - May 9 at 4:01 PM
	Transition Therapeutics Ord (NASDAQ:TTHI) Shorted Shares Decreased By 8.42% - B.O.D.Y Confidential (NASDAQ:TTHI) www.bodyconfidential.com - April 29 at 9:32 AM
	Transition Therapeutics (TTHI) Commences Dosing in TT701 Phase 2 in Androgen Deficiency - StreetInsider.com (NASDAQ:TTHI) www.streetinsider.com - April 26 at 9:48 AM
	Transition Therapeutics Announces Dosing of First Patient in Phase 2 Study of Drug Candidate TT701 (NASDAQ:TTHI) finance.yahoo.com - April 25 at 4:01 PM
	Transition Therapeutics Ord (NASDAQ:TTHI) Sellers Covered 8.42% of Their Shorts - CCH Daily News (NASDAQ:TTHI) cchdailynews.com - April 24 at 8:49 AM
	Latest Analyst Ratings For Transition Therapeutics, Inc. (TTHI) - Share Trading News (NASDAQ:TTHI) www.sharetrading.news - April 22 at 9:53 AM
	Broker Roundup For Transition Therapeutics, Inc. (TTHI) - Share Trading News (NASDAQ:TTHI) www.sharetrading.news - April 21 at 9:56 AM
	Biotech Stocks Inside Traders Spotlight: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) , Transition Therapeutics, Inc ... - WsNews 4investors (NASDAQ:TTHI) www.wsnews4investors.com - April 19 at 10:17 AM
	AstraZeneca plc (NYSE:AZN) & Transition Therapeutics (NASDAQ:TTHI) Hot Stock's Alert - Wall Street 24 (NASDAQ:TTHI) wallstrt24.com - April 19 at 10:17 AM
	Active Stocks Need to Consider- M&T Bank (NYSE:MTB), Transition Therapeutics. (NASDAQ:TTHI), GlaxoSmithKline ... - Seneca Globe (NASDAQ:TTHI) www.senecaglobe.com - April 19 at 10:17 AM
	Transition: Lilly Not To Advance Diabetes Drug Candidate TT401 To Phase 3 (NASDAQ:TTHI) www.nasdaq.com - April 18 at 9:57 AM
	Transition Therapeutics (TTHI) Says Lilly (LLY) Won't Advance TT401 into Phase 3 (NASDAQ:TTHI) www.streetinsider.com - April 18 at 9:57 AM
	Transition Therapeutics Inc to advance diabetes drug without Eli Lilly (NASDAQ:TTHI) www.proactiveinvestors.com - April 18 at 9:57 AM
	Transition Therapeutics Provides Update On Type 2 Diabetes Drug Candidate TT401 (NASDAQ:TTHI) www.thestreet.com - April 18 at 6:34 AM
	Making Impressive Motion: Transition Therapeutics Inc. (NASDAQ:TTHI), Sumitomo Mitsui Financial Group (NYSE ... - Property Mentor (NASDAQ:TTHI) www.propertymentorgroup.com - April 14 at 2:14 PM
	After Last Week What Do Analysts Think Of Transition Therapeutics, Inc. (TTHI) - Share Trading News (NASDAQ:TTHI) www.sharetrading.news - April 12 at 12:50 PM
	Transition Therapeutics, Inc. (TTHI) Updated Broker Price Targets - Share Trading News (NASDAQ:TTHI) www.sharetrading.news - April 9 at 12:12 PM
	Transition Therapeutics, Inc. (TTHI) - Broker Update - Risers & Fallers (NASDAQ:TTHI) www.risersandfallers.com - April 9 at 12:12 PM
	Transition Therapeutics Ord (NASDAQ:TTHI) Short Interest Decreased By 5.4% - Stock Caller (NASDAQ:TTHI) www.stockcaller.com - April 5 at 2:22 PM
	Transition Therapeutics Receives Notification From NASDAQ (NASDAQ:TTHI) finance.yahoo.com - March 17 at 5:01 PM
	Transition Therapeutics to Present at the 36th Annual Cowen Healthcare Conference (NASDAQ:TTHI) finance.yahoo.com - March 1 at 4:30 PM
	DETROIT — The moon turned blue on Tuesday and a pig was spotted flying near the Ottawa airport (NASDAQ:TTHI) www.ad-hoc-news.de - February 10 at 12:33 PM
	Transition Therapeutics posts 2Q loss (NASDAQ:TTHI) sg.finance.yahoo.com - February 9 at 6:29 PM
	Transition Therapeutics Announces Second Quarter Fiscal 2016 Financial Results (NASDAQ:TTHI) finance.yahoo.com - February 9 at 4:30 PM
	Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2016 Financial Results on Tuesday, February 9th, at 4:30 P.M. EST (NASDAQ:TTHI) finance.yahoo.com - February 5 at 1:01 PM
	Transition Therapeutics Announces Top Line Phase 2 Clinical Study Results of Diabetes Drug Candidate TT401 (NASDAQ:TTHI) finance.yahoo.com - February 1 at 6:01 AM
	Transition Therapeutics Announces Annual General Meeting Voting Results (NASDAQ:TTHI) finance.yahoo.com - January 6 at 6:01 AM
	TRANSITION THERAPEUTICS INC. Financials (NASDAQ:TTHI) finance.yahoo.com - December 8 at 1:15 PM
	Transition Therapeutics to Host Investor Day November 23 in New York (NASDAQ:TTHI) finance.yahoo.com - November 19 at 11:45 AM
	Transition Therapeutics posts 1Q loss (NASDAQ:TTHI) sg.finance.yahoo.com - November 10 at 4:21 PM
	Transition Therapeutics Announces First Quarter Fiscal 2016 Financial Results (NASDAQ:TTHI) finance.yahoo.com - November 10 at 4:01 PM
	Appointment of Non-Executive Director (G Pace) (NASDAQ:TTHI) www.noodls.com - November 8 at 8:26 PM
	Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2016 Financial Results on Tuesday, November 10th, at 4:30 P.M. EST (NASDAQ:TTHI) finance.yahoo.com - November 2 at 6:01 AM
	Transition Therapeutics Announces Agreement for Phase 2 Study of TT701 Drug Candidate (NASDAQ:TTHI) finance.yahoo.com - October 29 at 4:01 PM